Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]
Ooi CJ +34 more
europepmc +1 more source
Factors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea. [PDF]
Choi MS +5 more
europepmc +1 more source
The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy. [PDF]
Lemiesz P +3 more
europepmc +1 more source
Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan. [PDF]
Igarashi A +6 more
europepmc +1 more source
Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis. [PDF]
Chaiyabutr C +6 more
europepmc +1 more source
Case Report: Upadacitinib and apremilast combination therapy for guselkumab-induced paradoxical eczema in psoriasis. [PDF]
Yang L, Zhou J, Ruan Z, Shi K.
europepmc +1 more source
Markedly improved disease control in Darier disease (<i>ATP2A2</i>-nonsyndromic epidermal differentiation disorder) with ustekinumab versus other biologics: a case series. [PDF]
Skarnvad Andersen A +5 more
europepmc +1 more source
First-Line Guselkumab Combined with Exclusive Enteral Nutrition in Biologic-Naïve Young‑Onset Crohn's Disease: A Three-Case Series from China. [PDF]
Sha S +8 more
europepmc +1 more source
Interleukin-23 Inhibitors in Inflammatory Bowel Disease. [PDF]
Puca P +8 more
europepmc +1 more source
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study. [PDF]
Conforti A +73 more
europepmc +1 more source

